KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $104.6 million.

  • Regeneron Pharmaceuticals' Shares Outstanding (Weighted Average) fell 305.84% to $104.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $104.6 million, marking a year-over-year decrease of 305.84%. This contributed to the annual value of $104.6 million for FY2025, which is 305.84% down from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Shares Outstanding (Weighted Average) stood at $104.6 million for Q4 2025, which was down 305.84% from $105.1 million recorded in Q3 2025.
  • Regeneron Pharmaceuticals' 5-year Shares Outstanding (Weighted Average) high stood at $108.1 million for Q2 2024, and its period low was $104.6 million during Q4 2025.
  • In the last 5 years, Regeneron Pharmaceuticals' Shares Outstanding (Weighted Average) had a median value of $106.8 million in 2022 and averaged $106.7 million.
  • In the last 5 years, Regeneron Pharmaceuticals' Shares Outstanding (Weighted Average) plummeted by 410.21% in 2021 and then surged by 256.65% in 2022.
  • Over the past 5 years, Regeneron Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $105.7 million in 2021, then increased by 1.32% to $107.1 million in 2022, then dropped by 0.37% to $106.7 million in 2023, then grew by 1.12% to $107.9 million in 2024, then decreased by 3.06% to $104.6 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $104.6 million for Q4 2025, versus $105.1 million for Q3 2025 and $105.9 million for Q2 2025.